Reaction Biology Awarded NIH SBIR Grant
Complete the form below to unlock access to ALL audio articles.
Reaction Biology Corporation ("RBC") has announced that it has been awarded an SBIR grant from the National Cancer Institute to create a kinase profiling and high throughput screening method using radioisotopes and microarrays.
The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC’s DiscoveryDot™ nanoliter screening platform.
While screening kinase activity with radioisotope detection is considered by many in the drug-discovery industry to be the "gold standard" of kinase assays, use of the format is limited by expense and the difficulty of radioactive disposal.
The DiscoveryDot™ platform uses only a fraction of the reagents compared to well plate methods.
"Due to our nano-scale format, the amount of radioisotope used in the process should be minimal," said RBC Chief Technology Officer Haiching Ma, Ph.D.
"This should lead to far fewer disposal and handling problems, and reduced cost overall."
